查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1806329

自体免疫疾病诊断市场（按产品、检测、样本类型、适应症和最终用户划分）—2025 年至 2030 年全球预测

Autoimmune Disease Diagnostics Market by Product, Test, Sample Type, Indication, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

自体免疫疾病诊断市场预计到 2024 年将达到 58 亿美元，到 2025 年将达到 62.2 亿美元，到 2030 年将达到 89 亿美元，复合年增长率为 7.38%。

主要市场统计数据
基准年2024年 58亿美元
预计2025年 62.2亿美元
预测年份 2030 89亿美元
复合年增长率（%） 7.38%

无与伦比的分析严谨性和新技术进步为自体免疫疾病诊断的新时代奠定了基础

自体免疫疾病的日益流行，推动了对兼具准确性、快速性和可靠性的诊断解决方案的需求。临床医生和实验室专业人员面临越来越大的鑑别复杂病理的压力，因此快速识别免疫异常的能力至关重要。在此背景下，创新技术与先进分析技术的融合正在改变自体免疫疾病的识别和监测方式，最终改善患者预后并优化护理路径。

利用最尖端科技和以患者为中心的方法，实现自体免疫疾病诊断的模式转移

自体免疫诊断领域正在经历模式转移，这得益于次世代定序、新型生物标记发现和照护现场技术的整合。单一标记检测的时代已经一去不復返；如今，多重免疫学检测组合能够全面洞察复杂的免疫反应，从而实现精准的疾病分类和个性化的治疗策略。这种转变正在重新定义实验室科学与临床决策之间的关係，促进更具协作性、多学科的病患管理方法。

评估2025年美国新关税政策对自体免疫疾病诊断市场的深远影响

2025年美国修订的关税政策将为自体免疫诊断供应链带来新的复杂性。进口检测试剂套件和专用设备零件的关税上调，促使製造商重新评估筹资策略，许多製造商正在探索近岸外包选项以缓解成本压力。随着製造成本的上升，企业正在寻求透过流程优化和与策略供应商合作来保护净利率。

解读影响诊断创新的产品、测试、检体、适应症和最终用户类别的关键市场区隔动态

了解市场区隔的细微差别，有助于诊断服务提供者客製化产品以满足客户需求。将耗材和检测试剂套件与检测设备进行比较，可以发现耗材部分通常是经常性收益来源，而检测设备则是实验室基础设施的策略性资本投资。透过客製化产品系列平衡这些依赖关係，公司可以优化现金流，同时与诊断实验室和医院建立长期合作伙伴关係。

探索美洲、中东和非洲以及亚太地区自体免疫诊断市场的区域差异和市场驱动因素

自体免疫诊断的区域动态反映了临床重点、法规环境和医疗服务模式的多样性。在美洲，对精准医疗的高度重视推动了多重检测和次世代定序检测的快速应用，而完善的报销框架也促进了公立和私立医疗机构的可及性。同时，供应商正在扩大区域配送中心，以简化物流并提升服务应对力。

评估推动自体免疫疾病诊断创新的主要企业的竞争策略和策略联盟

领先的诊断公司正在部署多管齐下的策略，以确保在自体免疫疾病检测领域中占据竞争优势。策略联盟、合资企业和授权协议正在推动新型检测化学方法和数位分析能力的快速整合。透过这些伙伴关係关係，各公司可以共用开发风险和资本投入，同时加速突破性诊断产品的上市时间。

制定可行的策略建议，帮助产业领导者应对市场波动并抓住诊断市场机会

产业领导者必须优先将先进的分析平台与现有的实验室资讯系统整合，以挖掘更深入的诊断见解。建立强大的数据管道，使企业能够利用真实世界证据，提升检测性能，识别新的生物标记特征，并透过令人信服的临床检验支持监管申报。

揭示这项全面的自体免疫疾病诊断市场研究背后严谨的调查方法和分析框架

本研究采用多维度的调查方法，旨在提供对自体免疫诊断市场的客观全面分析。主要研究包括访谈关键意见领袖、实验室主任和采购专家，以收集新兴需求、技术偏好和购买行为的定性见解。同时，次要研究则系统性地回顾了科学文献、监管备案文件和专利资料库，以追踪技术创新轨迹和核准时间表。

综合阐述自体免疫疾病诊断策略重要性的关键见解与未来观点

这些见解的综合体现出，市场正处于转型期，其特点是技术融合、监管格局不断变化以及对个人化诊断的日益重视。随着多重免疫测量、次世代定序和数位分析成为临床工作流程的核心，相关人员必须保持敏捷，抓住新机会，并回应不断变化的临床需求。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 推出远端医疗、整合智慧型手机连线的家庭自体免疫疾病检测套组
  • 采用数位健康平台进行远端订购和解释自体免疫诊断测试的人数激增
  • 扩展个人化蛋白质体学和代谢体学学生物标记组用于第 1 型糖尿病的预测诊断
  • 基于液态生物检体的游离DNA甲基化检测在监测多发性硬化症治疗效果的应用
  • 开发用于临床快速自体免疫诊断的照护现场多重生物标记检测装置
  • 将人工智慧演算法融入免疫检测分析以提高诊断准确性
  • 使用次世代定序抗体组合进行类风湿性关节炎和狼疮的早期检测

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章自体免疫疾病诊断市场（按产品）

  • 耗材和检测试剂套件
  • 装置

第九章自体免疫疾病诊断市场（按测试）

  • 自体抗体和免疫学检测
  • 发炎标记物
  • 定期进行实验室检查

第 10 章自体免疫疾病诊断市场（按样本类型）

  • 血
  • 唾液
  • 尿

第 11 章自体免疫疾病诊断市场（按适应症）

  • 器官特异性自体免疫疾病诊断
    • 葛瑞夫兹氏病
    • 桥本氏症
    • 多发性硬化症
    • 1型糖尿病
  • 自体免疫疾病的系统性诊断
    • 类风湿性关节炎（RA）
    • 全身性红斑性狼疮（SLE）
    • 系统性硬皮症（硬皮症）

第 12 章自体免疫疾病诊断市场（按最终用户）

  • 门诊治疗中心
  • 诊断实验室
  • 医院和诊所
  • 研究机构

13.美国自体免疫免疫疾病诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 欧洲、中东和非洲的自体免疫疾病诊断市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

15. 亚太地区自体免疫疾病诊断市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • AESKU.GROUP GmbH & Co. KG
    • Bio-Rad Laboratories, Inc.
    • BioAgilytix Labs
    • Biogenuix Medsystems Private Limited
    • bioMerieux SA
    • Danaher Corporation
    • DSS Imagetech Pvt. Ltd.
    • Exagen Inc.
    • F. Hoffmann-La Roche Ltd.
    • Grifols, SA
    • Hemagen Diagnostics, Inc.
    • Labcorp Holdings Inc.
    • Medical & Biological Laboratories Co. Ltd
    • Menarini Group
    • Merck KGaA
    • Progentec Diagnostics, Inc.
    • Quest Diagnostics
    • Revvity, Inc.
    • RSR Limited
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Trinity Biotech PLC
    • Werfen Group

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

Product Code: MRR-436901065F36

The Autoimmune Disease Diagnostics Market was valued at USD 5.80 billion in 2024 and is projected to grow to USD 6.22 billion in 2025, with a CAGR of 7.38%, reaching USD 8.90 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.80 billion
Estimated Year [2025] USD 6.22 billion
Forecast Year [2030] USD 8.90 billion
CAGR (%) 7.38%

Setting the Stage for a New Era in Autoimmune Disease Diagnostics Through Unparalleled Analytical Rigor and Emerging Technological Advances

The increasing prevalence of autoimmune disorders has amplified the need for diagnostic solutions that combine precision, speed, and reliability. As clinicians and laboratory professionals face growing demands to distinguish among complex disease presentations, the ability to pinpoint immune dysregulation swiftly becomes critical. Amid this backdrop, a convergence of innovative technologies and refined analytical techniques is transforming how autoimmune conditions are identified and monitored, ultimately enhancing patient outcomes and optimizing care pathways.

Advancements in immunodiagnostic platforms are reshaping traditional workflows, enabling multiplex assays and high-throughput screening to deliver comprehensive profiles from minimal sample volumes. Integration of machine learning algorithms into diagnostic algorithms further refines signal detection, resulting in reduced false positives and expedited turnaround times. Consequently, laboratories are becoming more agile and responsive, leveraging these technological breakthroughs to meet evolving clinical requirements.

This executive summary synthesizes the most pertinent developments influencing autoimmune disease diagnostics today. It offers a strategic overview designed to inform decision-makers, guiding them through emerging landscape shifts, regulatory influences, and segmentation nuances. By framing the critical drivers and barriers shaping this domain, the introduction sets the stage for a detailed examination of market transformations and actionable recommendations that follow.

Unveiling the Paradigm Shift in Autoimmune Disease Diagnostics Driven by Cutting-Edge Technologies and Patient-Centric Approaches

The autoimmune diagnostics field is experiencing a paradigm shift, propelled by the integration of next-generation sequencing, novel biomarker discovery, and point-of-care technologies. Gone are the days when single-marker tests dominated; today, multiplex immunologic panels offer holistic insights into complex immune responses, enabling precise disease classification and tailored treatment strategies. This shift is redefining the relationship between laboratory science and clinical decision-making, fostering a more collaborative, multidisciplinary approach to patient management.

Furthermore, the rise of patient-centric models has spurred the development of minimally invasive sampling techniques. Saliva- and urine-based assays are gaining traction alongside conventional blood tests, as they enhance patient compliance and broaden testing access in outpatient and ambulatory care settings. Consequently, diagnostics providers are investing in robust platforms capable of accommodating diverse sample matrices without compromising analytical performance.

In parallel, regulatory agencies are refining guidelines to ensure assay accuracy and reproducibility while expediting approval pathways for breakthrough technologies. These evolving frameworks are encouraging manufacturers to accelerate innovation cycles, driving competitive differentiation through novel assay chemistries and integrated data analytics. As a result, industry stakeholders are engaging in strategic collaborations and technology licensing agreements to harness complementary capabilities, signaling a new era of collective advancement in autoimmune disease diagnostics.

Assessing the Far-Reaching Consequences of New United States Tariff Policies on the Autoimmune Disease Diagnostics Market Through 2025

The introduction of revised United States tariff policies in 2025 has injected new complexities into the supply chain for autoimmune diagnostics. Increased duties on imported assay kits and specialized instrument components have led manufacturers to reevaluate sourcing strategies, with many exploring nearshoring options to mitigate cost pressures. As production costs climb, companies are seeking to preserve margins through process optimization and strategic supplier partnerships.

Moreover, the elevated tariffs have prompted a reassessment of distribution networks. Distributors and laboratory purchasers are negotiating pricing models more aggressively and exploring consolidated procurement agreements to achieve economies of scale. In response, diagnostics companies are offering value-added services-such as instrument maintenance packages and reagent leasing programs-to differentiate their value propositions and maintain customer loyalty amid pricing volatility.

Despite these headwinds, the industry has demonstrated resilience. Manufacturers are leveraging local contract manufacturing and in-market reagent assembly to offset tariff impacts. Additionally, investments in modular instrument design are enabling rapid component interchangeability, which reduces reliance on specific imported parts. Through these adaptive measures, stakeholders are maintaining supply continuity and safeguarding analytical quality, ensuring that patients continue to receive timely and accurate autoimmune disease diagnoses.

Deciphering Critical Market Segmentation Dynamics Across Product, Test, Sample, Indication, and End User Categories Shaping Diagnostic Innovation

A nuanced understanding of market segmentation reveals how diagnostic providers can tailor their offerings to distinct customer needs. When examining consumables and assay kits alongside instruments, it becomes clear that the consumables segment often drives recurring revenue streams, whereas instruments represent strategic capital investments in laboratory infrastructure. By aligning product portfolios to balance these dependencies, companies can optimize cash flow while fostering long-term partner relationships with diagnostic laboratories and hospitals.

Shifting focus to test categories underscores the critical role of autoantibody and immunologic assays in delivering specificity, while inflammatory marker tests support broader disease monitoring applications. Routine laboratory tests continue to form the diagnostic backbone, particularly in primary care settings where screening for autoimmune indicators often precedes specialized analysis. Integrating these test modalities within a cohesive diagnostic ecosystem empowers clinicians to navigate the full spectrum of patient presentations more effectively.

Sample type considerations further refine targeting strategies. Blood remains the gold standard for most applications, yet saliva and urine matrices offer compelling advantages for decentralized testing. By developing platforms that accommodate diverse sample inputs, companies can unlock new end-user segments, from research institutions exploring novel biomarkers to ambulatory centers seeking rapid, noninvasive diagnostics.

Considering disease indication, organ-specific diagnostics for conditions such as Graves' disease, Hashimoto's thyroiditis, multiple sclerosis, and type 1 diabetes continue to expand alongside systemic autoimmune panels for rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis. This dual focus underscores the importance of tailored assay development and robust clinical validation protocols. Finally, end-user segmentation-spanning ambulatory care centers, diagnostic laboratories, hospitals and clinics, and research institutions-highlights the importance of customized support services, training programs, and localized marketing initiatives to maximize adoption and utilization.

Exploring Regional Variations and Growth Drivers Across the Americas, Europe Middle East Africa, and Asia-Pacific Autoimmune Diagnostics Markets

Regional dynamics in autoimmune diagnostics reflect a mosaic of clinical priorities, regulatory environments, and healthcare delivery models. In the Americas, the emphasis on precision medicine is driving rapid adoption of multiplex and next-generation sequencing-based assays, with well-established reimbursement frameworks facilitating access in both public and private healthcare settings. Meanwhile, suppliers are expanding regional distribution hubs to streamline logistics and enhance service responsiveness.

Across Europe, the Middle East and Africa, regulatory harmonization efforts are influencing market entry strategies. In Europe, robust centralized approval mechanisms support the integration of innovative diagnostic technologies, while in many Middle Eastern and African markets, capacity-building initiatives are fostering collaborations between local laboratories and global diagnostics providers. These partnerships are critical for addressing infrastructure gaps and training needs, ultimately improving diagnostic reach and reliability in emerging markets.

The Asia-Pacific region presents a tapestry of growth opportunities characterized by diverse regulatory landscapes and burgeoning investment in healthcare infrastructure. Countries with rapidly expanding laboratory networks are prioritizing the implementation of high-sensitivity immunoassays to tackle rising autoimmune disease prevalence. Concurrently, local manufacturers are partnering with multinational firms to localize production, reducing lead times and enhancing affordability for large patient populations. Collectively, these regional strategies underscore the need for flexible market entry models that accommodate varied clinical, regulatory, and economic conditions.

Evaluating Competitive Strategies and Strategic Collaborations Among Leading Companies Fueling Innovation in Autoimmune Disease Diagnostics

Leading diagnostics companies are deploying multifaceted strategies to secure competitive advantage in autoimmune disease testing. Strategic collaborations, joint ventures, and licensing agreements are enabling rapid integration of novel assay chemistries and digital analytics capabilities. Through these partnerships, firms are accelerating time to market for breakthrough diagnostics while sharing development risks and capital investments.

Simultaneously, several companies are investing in modular instrument platforms that support a broad assay menu, thereby enhancing flexibility for end users and creating cross-selling opportunities for consumables and reagents. This integrated approach encourages laboratory consolidation around a single ecosystem, fostering long-term customer loyalty and driving higher lifetime value per account.

Moreover, a growing number of market leaders are enhancing their digital service offerings by embedding cloud-based data management and remote monitoring solutions into instrumentation. These capabilities not only improve operational efficiency and predictive maintenance but also enable real-time data analytics for epidemiological surveillance and cohort studies. By leveraging these digital infrastructures, companies are creating new avenues for value-added services and reinforcing their roles as strategic partners in clinical research and patient care.

Formulating Actionable Strategic Recommendations to Empower Industry Leaders to Navigate Disruption and Capitalize on Diagnostic Market Opportunities

Industry leaders must prioritize the integration of advanced analytics platforms with existing laboratory information systems to unlock deeper diagnostic insights. By establishing robust data pipelines, organizations can harness real-world evidence to refine assay performance, identify emerging biomarker signatures, and support regulatory submissions with compelling clinical validation.

In addition, forging strong alliances with academic research centers and specialized clinical networks will accelerate the co-development of next-generation assays. These collaborative ecosystems foster knowledge exchange and expedite the translation of novel biomarkers into clinically actionable tests. Consequently, companies can create differentiated value propositions and reinforce their reputations as innovation frontrunners.

Executives should also explore localized manufacturing and reagent assembly partnerships to mitigate geopolitical and tariff-related risks. This strategic decentralization ensures supply chain resilience and enhances responsiveness to regional demand fluctuations. Finally, investing in comprehensive training programs for technicians and clinicians will drive assay adoption and optimize diagnostic utility. By coupling product excellence with superior support services, organizations can secure long-term contracts and reinforce their leadership positions in a competitive landscape.

Elucidating the Rigorous Research Methodology and Analytical Framework Underpinning This Comprehensive Autoimmune Diagnostics Market Study

This study employs a multi-faceted research methodology to deliver an unbiased and comprehensive view of the autoimmune diagnostics landscape. Primary research interviews were conducted with key opinion leaders, laboratory directors, and procurement specialists to gather qualitative insights on emerging needs, technology preferences, and purchasing behaviors. In parallel, secondary research encompassed the systematic review of scientific publications, regulatory filings, and patent databases to track innovation trajectories and approval timelines.

Quantitative data was synthesized using a bottom-up analytical framework to ensure consistency across segmentation categories. Cross-validation between primary and secondary sources enhanced data reliability, while triangulation techniques were applied to reconcile discrepancies and verify emerging trends. Competitive benchmarking exercises provided clarity on each leading company's strategic positioning, product portfolios, and partnership networks.

Geographic analysis incorporated regional regulatory nuances, healthcare infrastructure assessments, and distribution channel evaluations. Throughout the study, rigorous quality control protocols-such as data audits and peer reviews-ensured the integrity and accuracy of findings. This robust methodology underpins the strategic recommendations and market insights presented herein, offering stakeholders a credible foundation for informed decision-making.

Synthesis of Core Insights and Forward-Looking Perspectives Cementing the Strategic Importance of Autoimmune Disease Diagnostics

The synthesis of these insights highlights a market in transition, characterized by technological convergence, shifting regulatory landscapes, and heightened emphasis on personalized diagnostics. As multiplex immunoassays, next-generation sequencing, and digital analytics become central to clinical workflows, stakeholders must remain agile to capture emerging opportunities and address evolving clinical demands.

Regional dynamics underscore the importance of tailored market entry strategies that align with local regulatory frameworks and healthcare infrastructure capabilities. Competitive pressures and tariff-related challenges necessitate resilient supply chain models and strategic collaborations to maintain continuity and cost efficiency.

Ultimately, the success of industry players will hinge on their ability to integrate advanced analytics with robust assay development, foster collaborative research ecosystems, and deliver value through comprehensive support services. By embracing these imperatives, organizations can solidify their positions as leaders in the autoimmune diagnostics realm and drive meaningful improvements in patient outcomes worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rise of telemedicine enabled home based autoimmune disease testing kits integrated with smartphone connectivity features
  • 5.2. Surge in adoption of digital health platforms for remote ordering and interpretation of autoimmune diagnostic tests
  • 5.3. Expansion of personalized proteomic and metabolomic biomarker panels for predictive type 1 diabetes diagnostics
  • 5.4. Implementation of liquid biopsy based cell free DNA methylation assays for monitoring multiple sclerosis treatment efficacy
  • 5.5. Development of point of care multiplex biomarker testing devices for rapid autoimmune diagnosis in clinical settings
  • 5.6. Integration of artificial intelligence algorithms in immunoassay analysis for improved diagnostic precision
  • 5.7. Adoption of next generation sequencing autoantibody panels for early rheumatoid and lupus detection

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Autoimmune Disease Diagnostics Market, by Product

  • 8.1. Introduction
  • 8.2. Consumables & Assay Kits
  • 8.3. Instruments

9. Autoimmune Disease Diagnostics Market, by Test

  • 9.1. Introduction
  • 9.2. Autoantibodies & Immunologic Test
  • 9.3. Inflammatory Markers
  • 9.4. Routine Laboratory Tests

10. Autoimmune Disease Diagnostics Market, by Sample Type

  • 10.1. Introduction
  • 10.2. Blood
  • 10.3. Saliva
  • 10.4. Urine

11. Autoimmune Disease Diagnostics Market, by Indication

  • 11.1. Introduction
  • 11.2. Organ-Specific Autoimmune Disease Diagnostics
    • 11.2.1. Graves' Disease
    • 11.2.2. Hashimoto's Thyroiditis
    • 11.2.3. Multiple Sclerosis
    • 11.2.4. Type 1 Diabetes
  • 11.3. Systemic Autoimmune Disease Diagnostics
    • 11.3.1. Rheumatoid Arthritis (RA)
    • 11.3.2. Systemic Lupus Erythematosus (SLE)
    • 11.3.3. Systemic Sclerosis (Scleroderma)

12. Autoimmune Disease Diagnostics Market, by End Users

  • 12.1. Introduction
  • 12.2. Ambulatory Care Centers
  • 12.3. Diagnostic Laboratories
  • 12.4. Hospitals & Clinics
  • 12.5. Research Institutions

13. Americas Autoimmune Disease Diagnostics Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Autoimmune Disease Diagnostics Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Autoimmune Disease Diagnostics Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. AESKU.GROUP GmbH & Co. KG
    • 16.3.3. Bio-Rad Laboratories, Inc.
    • 16.3.4. BioAgilytix Labs
    • 16.3.5. Biogenuix Medsystems Private Limited
    • 16.3.6. bioMerieux SA
    • 16.3.7. Danaher Corporation
    • 16.3.8. DSS Imagetech Pvt. Ltd.
    • 16.3.9. Exagen Inc.
    • 16.3.10. F. Hoffmann-La Roche Ltd.
    • 16.3.11. Grifols, S.A
    • 16.3.12. Hemagen Diagnostics, Inc.
    • 16.3.13. Labcorp Holdings Inc.
    • 16.3.14. Medical & Biological Laboratories Co. Ltd
    • 16.3.15. Menarini Group
    • 16.3.16. Merck KGaA
    • 16.3.17. Progentec Diagnostics, Inc.
    • 16.3.18. Quest Diagnostics
    • 16.3.19. Revvity, Inc.
    • 16.3.20. RSR Limited
    • 16.3.21. Siemens Healthineers AG
    • 16.3.22. Thermo Fisher Scientific Inc.
    • 16.3.23. Trinity Biotech PLC
    • 16.3.24. Werfen Group

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: RESEARCHAI
  • FIGURE 26. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 27. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: RESEARCHCONTACTS
  • FIGURE 28. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ASSAY KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ROUTINE LABORATORY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ROUTINE LABORATORY TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GRAVES' DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GRAVES' DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HASHIMOTO'S THYROIDITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HASHIMOTO'S THYROIDITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS (RA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS (RA), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC SCLEROSIS (SCLERODERMA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC SCLEROSIS (SCLERODERMA), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 66. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 67. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 68. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 69. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 71. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 73. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 75. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 77. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 81. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 82. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 83. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 84. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 85. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 87. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 88. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 91. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 92. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 93. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 94. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 95. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 96. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 97. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 98. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 99. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 100. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 101. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 103. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 104. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 105. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 106. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 107. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 108. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 109. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 110. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 111. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 112. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 113. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 114. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 115. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 118. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 119. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 120. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 121. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 122. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 123. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 124. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 125. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 126. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 127. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 128. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 129. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 130. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 131. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 132. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 133. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 134. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 135. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 136. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 137. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 138. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 139. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 140. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 141. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 142. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 143. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 145. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 146. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 147. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 148. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 149. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 150. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 151. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 152. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 169. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 170. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 177. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 179. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 181. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 183. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 184. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 185. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 186. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 187. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 189. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 190. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 191. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 192. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 193. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 194. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 195. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 196. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 197. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 198. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 199. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 200. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 201. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 204. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 205. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 206. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 207. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 208. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 209. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 210. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 211. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 212. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 213. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 214. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 215. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 218. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 219. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 220. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 221. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 222. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 223. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 224. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 225. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 226. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 227. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 228. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 229. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 231. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 232. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 233. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 234. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 235. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 236. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 237. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 238. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 239. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 240. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 241. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 242. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 243. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 245. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 247. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 248. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 249. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 250. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 251. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 252. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 261. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 263. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 267. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 268. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 269. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 270. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 276. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 278. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 280. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 282. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 284. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 288. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 289. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 290. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNO